A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Paul Johnson
Advertisement
Paul Johnson is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Paul Johnson
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: October 2nd 2009 | Updated:
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
RNAnalytics’ Viktoria Enkmann Ponders Nanoparticle Characterization Advances at CPHI Frankfurt: Part One
5
